Annotation Detail
Information
- Associated Genes
- FLT3
- Associated Variants
-
FLT3 ITD
FLT3 ITD - Associated Disease
- leukemia
- Source Database
- CIViC Evidence
- Description
- In a preclinical trial, the leukemic cell line MV4-11 with the FLT3-ITD mutation and the leukemic cell line RS4;11 with the native FLT3 gene were treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was similarly effective in the growth inhibition of cells harboring the FLT3-ITD mutation (IC50=2 nmol/L) compared to sorafenib (IC50=4 nmol/L) and sunitinib (IC50=12 nmol/L). Conversely, all three TKIs each were not effective in the growth inhibition of cells with native FLT3 (IC50>100 nmol/L).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7382
- Gene URL
- https://civic.genome.wustl.edu/links/genes/24
- Variant URL
- https://civic.genome.wustl.edu/links/variants/55
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Leukemia
- Evidence Direction
- Supports
- Drug
- Sunitinib,Sorafenib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 21482694